Sandbox MEN 2 epi: Difference between revisions

	Multiple endocrine neoplasia type 2 Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Multiple endocrine neoplasia type 2 from other Diseases
Epidemiology & Demographics
Risk Factors
Screening
Natural History, Complications & Prognosis
Diagnosis
Diagnostic Criteria
History & Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Sandbox MEN 2 epi On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Sandbox MEN 2 epi All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Sandbox MEN 2 epi
CDC on Sandbox MEN 2 epi
Sandbox MEN 2 epi in the news
Blogs on Sandbox MEN 2 epi
Directions to Hospitals Treating Multiple endocrine neoplasia type 2
Risk calculators and risk factors for Sandbox MEN 2 epi

Latest revision as of 15:04, 22 September 2015

__NOTOC_

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]

- Worldwide, the prevalence of multiple endocrine neoplasia type 2 is 2.5 per 100,000 persons in 2010.
- In United States the prevalence of multiple endocrine neoplasia type 2 is 1 in 30,000 to 50,000 person.
- MEN2 has been reported in approximately 500 to 1000 families worldwide.^[1]
- 70-80% of all multiple endocrine neoplasia type 2 cases are MEN type 2A.

- In developed countries, the incidence of (insert disease state here) is _____ per 100,000 persons.

It can be found in all ages.
MEN 2B manifest in early infancy while MEN 2A and familial medullary thyroid carcinoma is found in adulthood.

The prevalence and incidence of multiple endocrine neoplasia type 2 does not vary by gender.

In United States the prevalence of multiple endocrine neoplasia type 2 is 1 in 30,000 to 50,000 person..

@@ Line 9: / Line 9: @@
 **Worldwide, the [[prevalence]] of multiple endocrine neoplasia type 2 is 2.5 per 100,000 persons in 2010.
 ** In United States the prevalence of multiple endocrine neoplasia type 2 is 1 in 30,000 to 50,000 person.
-** MEN2 has been reported in approximately 500 to 1000 families worldwide.<ref name="Orphanet">quoted from http://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=GB&Expert=653{{full}}</ref>
+** MEN2 has been reported in approximately 500 to 1000 families worldwide.<ref name=Orphanet>{{cite web | title = Orphanet| url =http://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=GB&Expert=653 }}</ref>
 ** 70-80% of all multiple endocrine neoplasia type 2 cases are MEN type 2A.